(Press-News.org) AUSTIN, Texas — Researchers at The University of Texas at Austin have devised a new method for enriching a group of the world's most expensive chemical commodities, stable isotopes, which are vital to medical imaging and nuclear power, as reported this week in the journal Nature Physics. For many isotopes, the new method is cheaper than existing methods. For others, it is more environmentally friendly.
A less expensive, domestic source of stable isotopes could ensure continuation of current applications while opening up opportunities for new medical therapies and fundamental scientific research.
Chemical elements often exist in nature as a blend of different variants called isotopes. To be useful in most applications, a single isotope has to be enriched, or separated out from the rest.
A combination of factors has created a looming shortage of some of the world's most expensive but useful stable isotopes.
Last year, the Government Accountability Office released a report warning that there may soon be a shortage of lithium-7, a critical component of many nuclear power reactors. Production of lithium-7 was banned in the U.S. because of environmental concerns, and it's unclear whether the current sources, in China and Russia, will continue meeting global demand.
One of the major sources of molybdenum-99, essential for medical imaging in tens of millions of heart, kidney and breast procedures each year, is an aging nuclear reactor in Canada that's expected to cease operations in 2016. Other valuable isotopes are produced by Cold War era machines known as calutrons operating in Russia. Their extreme age, high operating costs and regional concentration further threaten global supply.
"Isotopes are among the most expensive commodities on Earth," says Mark Raizen, professor of physics in The University of Texas at Austin's College of Natural Sciences and author on the study. "One ounce of a stable isotope that needs the calutron to separate it can run around $3 million. That's roughly 2,000 times the price of gold. And that has held back certain medical therapies."
Unlike the calutron, which requires huge amounts of energy to maintain a magnetic field with electromagnets, the new method for enriching stable isotopes, called MAGIS (magnetically activated and guided isotope separation), needs little energy due to its use of low-powered lasers and permanent magnets. It also has less potential for environmental effects than the chemical process used in producing lithium-7, which has been linked to mercury contamination.
View an animation of the MAGIS device in action and read more about how it works here: https://www.youtube.com/watch?v=zIRi-7AxFAM.
Nuclear medicine in particular could benefit from the new method, the researchers say. Many stable isotopes are precursors to the short-lived radioisotopes used in medical imaging, cancer therapies and nutritional diagnostics.
The new method also has the potential to enhance our national security. The researchers used the method to enrich lithium-7, crucial to the operation of most nuclear reactors. The U.S. depends on the supply of lithium-7 from Russia and China, and a disruption could cause the shutdown of reactors. Other isotopes can be used to detect dangerous nuclear materials arriving at U.S. ports.
Raizen's co-authors on the paper are Tom Mazur, a Ph.D. student at the university; and Bruce Klappauf, a software developer at Enthought and a former senior research scientist at UT Austin.
Now, Raizen's top goal is getting this technology out of the lab and into the world. The MAGIS invention has been issued a U.S. patent, which is owned by The University of Texas at Austin, with Raizen and Klappauf as inventors.
Raizen plans to create a nonprofit foundation to license the technology.
"I believe this is world-changing in a way that is unique among all the projects that I have done. And I do feel passionately about it," said Raizen. "There are many potential uses of isotopes that we don't even know yet. But they've been held back because the price has been so high, or it's been unavailable. That will be one of the missions of the foundation — to explore and develop isotopes to benefit humanity."
Some critics have raised concerns about the potential for terrorists or rogue states to use MAGIS to enrich uranium for nuclear weapons. Raizen believes these concerns are unfounded given uranium's unique chemical characteristics. Read an online debate between Raizen and Francis Slakey, a physicist and associate director of public affairs for the American Physical Society here: http://www.aps.org/publications/apsnews/201301/backpage.cfm.
INFORMATION:
This research was funded by The University of Texas at Austin.
The University of Texas at Austin is committed to transparency and disclosure of all potential conflicts of interest of its researchers. Dr. Raizen has submitted required financial disclosure forms with the university. He has received research funding for other projects from the Texas Higher Education Coordinating Board, the Welch Foundation, the National Science Foundation and the U.S. Department of Energy. Klappauf and Mazur have no financial ties to the isotope industry or isotope consumers.
More Info
For a global map showing where molybdenum-99 (Mo-99) is enriched, the steps to produce it and the challenges to the global supply, go to: http://www.mallinckrodt.com/Nuclear_Imaging/Global_Mo-99_Supply_Chain.aspx
Improved method for isotope enrichment could secure a vital global commodity
2014-06-29
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Improved survival with TAS-102 in mets colorectal cancer refractory to standard therapies
2014-06-28
The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.
"Around 50% of patients with colorectal cancer develop metastases but eventually many of them do not respond to standard therapies," said Takayuki Yoshino of the National Cancer Centre Hospital East in Chiba, Japan, lead author of the phase III RECOURSE trial. "The RECOURSE study shows that TAS-102 improves overall ...
Cetuximab or bevacizumab with combi chemo equivalent in KRAS wild-type MCRC
2014-06-28
For patients with KRAS wild-type untreated colorectal cancer, adding cetuximab or bevacizumab to combination chemotherapy offers equivalent survival, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona.
"The CALGB/SWOG 80405 trial was designed and formulated in 2005, and the rationale was simple: we had new drugs --bevacizumab and cetuximab-- and the study was designed to determine if one was better than the other in first-line for patients with colon cancer," said lead study author Alan P. Venook, distinguished Professor of Medical ...
Herpes virus infection drives HIV infection among non-injecting drug users in New York
2014-06-27
HIV and its transmission has long been associated with injecting drug use, where hypodermic syringes are used to administer illicit drugs. Now, a newly reported study by researchers affiliated with New York University's Center for Drug Use and HIV Research (CDUHR) in the journal PLOS ONE, shows that HIV infection among heterosexual non-injecting drug users (no hypodermic syringe is used; drugs are taken orally or nasally) in New York City (NYC) has now surpassed HIV infection among persons who inject drugs.
The study, "HSV-2 Co-Infection as a Driver of HIV Transmission ...
Potential Alzheimer's drug prevents abnormal blood clots in the brain
2014-06-27
Without a steady supply of blood, neurons can't work. That's why one of the culprits behind Alzheimer's disease is believed to be the persistent blood clots that often form in the brains of Alzheimer's patients, contributing to the condition's hallmark memory loss, confusion and cognitive decline.
New experiments in Sidney Strickland's Laboratory of Neurobiology and Genetics at Rockefeller University have identified a compound that might halt the progression of Alzheimer's by interfering with the role amyloid-β, a small protein that forms plaques in Alzheimer's brains, ...
'Bad' video game behavior increases players' moral sensitivity
2014-06-27
BUFFALO, N.Y. — New evidence suggests heinous behavior played out in a virtual environment can lead to players' increased sensitivity toward the moral codes they violated.
That is the surprising finding of a study led by Matthew Grizzard, PhD, assistant professor in the University at Buffalo Department of Communication, and co-authored by researchers at Michigan State University and the University of Texas, Austin.
"Rather than leading players to become less moral," Grizzard says, "this research suggests that violent video-game play may actually lead to increased moral ...
Ancient ocean currents may have changed pace and intensity of ice ages
2014-06-27
Climate scientists have long tried to explain why ice-age cycles became longer and more intense some 900,000 years ago, switching from 41,000-year cycles to 100,000-year cycles.
In a paper published this week in the journal Science, researchers report that the deep ocean currents that move heat around the globe stalled or may have stopped at that time, possibly due to expanding ice cover in the Northern Hemisphere.
"The research is a breakthrough in understanding a major change in the rhythm of Earth's climate, and shows that the ocean played a central role," says ...
Research gives unprecedented 3-D view of important brain receptor
2014-06-27
PORTLAND, Ore. — Researchers with Oregon Health & Science University's Vollum Institute have given science a new and unprecedented 3-D view of one of the most important receptors in the brain — a receptor that allows us to learn and remember, and whose dysfunction is involved in a wide range of neurological diseases and conditions, including Alzheimer's, Parkinson's, schizophrenia and depression.
The unprecedented view provided by the OHSU research, published online June 22 in the journal Nature, gives scientists new insight into how the receptor — called the NMDA receptor ...
Study: To address climate change, nothing substitutes for reducing CO2 emissions
2014-06-27
The politically expedient way to mitigate climate change is essentially no way at all, according to a comprehensive new study by University of Chicago climatologist Raymond Pierrehumbert.
Among the climate pollutants humans put into the atmosphere in significant quantities, the effects of carbon dioxide (CO2) are the longest-lived, with effects on climate that extend thousands of years after emissions cease. But finding the political consensus to act on reducing CO2 emissions has been nearly impossible. So there has been a movement to make up for that inaction by reducing ...
Some aggressive cancers may respond to anti-inflammatory drugs
2014-06-27
New research raises the prospect that some cancer patients with aggressive tumors may benefit from a class of anti-inflammatory drugs used to treat rheumatoid arthritis.
Studying triple-negative breast cancer, researchers at Washington University School of Medicine in St. Louis found that some aggressive tumors rely on an antiviral pathway that appears to drive inflammation, widely recognized for roles in cancer, rheumatoid arthritis and other inflammatory diseases.
The tumors that activate this particular antiviral pathway always have dysfunctional forms of the proteins ...
Diamond plates create nanostructures through pressure, not chemistry
2014-06-27
ALBUQUERQUE, N.M. — You wouldn't think that mechanical force — the simple kind used to eject unruly patrons from bars, shoe a horse or emboss the raised numerals on credit cards — could process nanoparticles more subtly than the most advanced chemistry.
Yet, in a current paper in Nature Communications, Sandia National Laboratories researcher Hongyou Fan and colleagues appear to have achieved a start toward that end.
Their newly patented and original method uses simple pressure — a kind of high-tech embossing — to produce finer and cleaner results in forming silver ...